Trips and Neurotransmitters: Discovering Principled Patterns across 6,850 Hallucinogenic Experiences
Analysing 6,850 free-form testimonials across 27 hallucinogens with 40 neurotransmitter receptor proxies mapped to brain coordinates, the study uses pattern-learning to link distinct subjective experience themes to cortex-wide receptor density distributions. It finds that ego-dissolution relates to a 5-HT2A, D2, KOR and NMDA receptor constellation anchored in higher-order associative and visual cortices, and more broadly identifies association–sensory gradients that map the semantic structure of psychedelic experiences onto brain receptor architecture with potential therapeutic implications.
Authors
- Ballentine, G.
- Friedman, S. F.
- Bzdok, D.
Published
Abstract
Psychedelics are thought to alter states of consciousness by disrupting how the higher association cortex governs bottom-up sensory signals. Individual hallucinogenic drugs are usually studied in participants in controlled laboratory settings. Here, we have explored word usage in 6,850 free-form testimonials with 27 drugs through the prism of 40 neurotransmitter receptor subtypes, which were then mapped to 3D coordinates in the brain via their gene transcription levels from invasive tissue probes. Despite the variable subjective nature of hallucinogenic experiences, our pattern-learning approach delineated how drug-induced changes of conscious awareness (e.g., dissolving self-world boundaries or fractal distortion of visual perception) are linked to cortex-wide anatomical distributions of receptor density proxies. The dominant explanatory factor related ego-dissolution-like phenomena to a constellation of 5-HT2A, D2, KOR, and NMDA receptors, anchored especially in the brain’s deep hierarchy (epitomized by the associative higher-order cortex) and shallow hierarchy (epitomized by the visual cortex). Additional factors captured psychological phenomena in which emotions (5-HT2A and Imidazoline1) were in tension with auditory (SERT, 5-HT1A) or visual (5-HT2A) sensations. Each discovered receptor-experience factor spanned between a higher-level association pole and a sensory input pole, which may relate to the previously reported collapse of hierarchical order among large-scale networks. Simultaneously considering many psychoactive molecules and thousands of natural language descriptions of drug experiences our framework finds the underlying semantic structure and maps it directly to the brain. These advances could assist in unlocking their wide-ranging potential for medical treatment.
Research Summary of 'Trips and Neurotransmitters: Discovering Principled Patterns across 6,850 Hallucinogenic Experiences'
Introduction
Hallucinogenic drugs alter consciousness through mechanisms involving multiple neurotransmitter systems, yet most neuroimaging and pharmacological research has focused on single compounds in controlled laboratory conditions, limiting the identification of general principles underlying drug-induced experiential change. The vast corpus of naturalistic psychedelic experience reports archived at the Erowid Center — an educational repository hosting first-person accounts of psychoactive substance use — offered an opportunity to approach this question empirically at scale. This study aimed to identify principled receptor-experience patterns linking neurotransmitter pharmacology to the phenomenological content of hallucinogenic states across 6,850 free-form testimonials and 27 drugs, and to locate these patterns anatomically in the brain using gene expression data from the Allen Human Brain Atlas.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Topics
- APA Citation
Ballentine, G., Friedman, S. F., & Bzdok, D. (2021). Trips and Neurotransmitters: Discovering Principled Patterns across 6,850 Hallucinogenic Experiences. https://doi.org/10.1101/2021.07.13.452263
References (30)
Papers cited by this study that are also in Blossom
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Newport, D. J., Carpenter, L. L., Mcdonald, W. M. et al. · American Journal of Psychiatry (2015)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Show all 30 referencesShow fewer
Swanson, L. R. · Frontiers in Pharmacology (2018)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Zamberlan, F., Sanz, C., Pallavicini, C. et al. · Frontiers in Integrative Neuroscience (2018)
Ray, T. S. · PLOS ONE (2010)
Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Carhart-Harris, R. L., Friston, K. J. · Brain (2010)
Rickli, A., Luethi, D., Reinisch, J. et al. · Neuropharmacology (2015)
Millière, R. · Frontiers in Human Neuroscience (2017)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Wittmann, M., Carter, O., Hasler, F. et al. · Journal of Psychopharmacology (2007)
Wittmann, M., Hasler, F., Vollenweider, F. X. · Neuroscience Letters (2008)
Cited By (2)
Papers in Blossom that reference this study
Aqil, M., Roseman, L. · Neuropharmacology (2022)
Tagliazucchi, E. · Frontiers in Pharmacology (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.